Skip to content
MarketScale
‹ Back to Industries

Sciences

Forging Connections: What Is the Cost of Not Being Digitally Smart?

With more than 18 years of experience as the founder, CEO, and president of Acumen Analytics, Kathleen Brunner’s love for numbers is evident. To talk about the key role data plays in solving problems, Brunner sits down with host Michelle Dawn Mooney. With today technological advancements, almost everything captures some form of data. The key…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · AnalyticsDataHoneywellInnovation
Share

Key takeaways

01

With more than 18 years of experience as the founder, CEO, and president of Acumen Analytics, Kathleen Brunner’s love for numbers is evident.

02

To talk about the key role data plays in solving problems, Brunner sits down with host Michelle Dawn Mooney.

03

With today technological advancements, almost everything captures some form of data.

With more than 18 years of experience as the founder, CEO, and president of Acumen Analytics, Kathleen Brunner’s love for numbers is evident. To talk about the key role data plays in solving problems, Brunner sits down with host Michelle Dawn Mooney.

With today technological advancements, almost everything captures some form of data. The key is “smart data…having data that’s effective, efficient, formatted in a way that can be acted upon and used for decision making, and leveraged in order to improve outcomes,” Brunner explained. For Acumen Analytics, their focus is on the healthcare industry and, specifically, the patient side of the business, which is why collecting the right data matters.

“When I talk about smart data, I’m talking about the ability to use advanced analytics and the power of data and technology,” Brunner said. Utilizing the right data can be both a differentiator and a transformational asset that can not only reduce costs but improve outcomes and accelerate problem solving. Poorly utilized data or lower data quality, however, can lead to bad decisions and higher costs, making it pertinent that the data is useable, clean, and in the desired format.

To start utilizing data, Brunner advises to look at areas that are silent, such as manual processes, and take “a look at where you can begin…this is the key to digital transformation.”

Acumen Analytics uses this innovative practice to accelerate and improve patient outcomes. With harmonized systems, Acumen transforms the patient experience. “I think the key to success is understanding where and which technology is relevant and then make your decision on investing,” Brunner explained.

Companies interested in utilizing smart data must be able to mitigate the risk around the transformation of technology. Brunner emphasized, “Make technology not the driver, but the enabler.”

To learn more visit the Sparta Systems and/or Honeywell Forge website(s).

About the author

S
Sciences

New to MarketScale?

MarketScale is the platform Sciences companies use to turn their own experts into content like this. Want the short overview?

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Tekniplex Showcases Sustainable Materials Innovation at Paris Packaging Week 2026

Tekniplex Showcases Sustainable Materials Innovation at Paris Packaging Week 2026

At Paris Packaging Week 2026, Tekniplex showcased its latest sustainable materials innovations, emphasizing the intersection of materials science and brand storytelling. The company's booth featured a living wall and digital displays to engage a sustainability-conscious audience, highlighting advanced materials for sustainability and product performance in cosmetics packaging.

  • 01Tekniplex emphasized sustainable materials innovation at Paris Packaging Week 2026.
  • 02The company's booth featured eco-friendly design elements and immersive digital displays.
  • 03Tekniplex highlighted advancements in recyclable sealing systems and materials for cosmetics.

Apr 9, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences